Furthermore, the levels of CXCL10 and CXCL11 in both AML‐PR and HSCT groups were significantly higher than those in the healthy control group, indicating that the increase of CXCL10 and CXCL11 in AML‐PR and HSCT patients may be associated with AML therapy. Here, CXCL11 is linked to acute myeloid leukemia.